SUSCCH
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hudec, Martin
DAPT-SHOCK-AMI, NCT03551964: Dual Antiplatelet Therapy for Shock Patients with Acute Myocardial Infarction

Active, not recruiting
4
605
Europe, RoW
Cangrelor, intravenous P2Y12 inhibitor, Ticagrelor, oral P2Y12 inhibitor
Faculty Hospital Kralovske Vinohrady, Charles University, Czech Republic
Acute Myocardial Infarction, Cardiogenic Shock
02/24
01/25
NCT03424941: The TransCatheter Valve and Vessels Trial

Active, not recruiting
N/A
172
Europe
FFR-guided PCI and TAVI, CABG and SAVR
Maatschap Cardiologie Zwolle, Medtronic
Aortic Stenosis, Multi Vessel Coronary Artery Disease, TAVI, CABG, PCI, Fractional Flow Reserve
04/24
11/24
LANDMARK, NCT04275726: Trial: a Randomised Controlled Trial of Myval THV

Recruiting
N/A
768
Europe, RoW
Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site.
Meril Life Sciences Pvt. Ltd.
Aortic Valve Stenosis
03/24
12/33
RFR-CABG, NCT04375306: Resting Full-cycle Flow Ratio (RFR) Versus Angiography to Guide Revascularization Strategy in Patients Undergoing Coronary Artery By-pass Grafting (CABG)

Recruiting
N/A
500
Europe
RFR guided CABG, Angio guided CABG
Diagram B.V.
Coronary Artery Disease
10/24
06/27
Hudec
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26

Download Options